(Q36715777)

English

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

scientific article published on February 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis (English)

1 reference

Europe PubMed Central

15 August 2017

2

object named as

John V Heymach

1 reference

Europe PubMed Central

15 August 2017

1

object named as

Roy S Herbst

1 reference

Europe PubMed Central

15 August 2017

Dr. Bianca Lins, LL.M.

4

object named as

Amir Onn

1 reference

Europe PubMed Central

15 August 2017

author name string

Michael S O'Reilly

3

1 reference

Europe PubMed Central

15 August 2017

Anderson J Ryan

5

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

1 February 2007

1 reference

Europe PubMed Central

15 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

15 August 2017

16

1 reference

Europe PubMed Central

15 August 2017

239-249

1 reference

Europe PubMed Central

15 August 2017

2

1 reference

Europe PubMed Central

15 August 2017

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Epidermal growth factor receptor inhibition strategies in oncology

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

RET and neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Emerging antiangiogenic agents in lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.239

21 January 2018

Identifiers

10.1517/13543784.16.2.239

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36715777&oldid=2112924631"